Form 4: Olema Director Rappaport Exercises Options, Gifts Shares

Olema Pharmaceuticals Director Andrew Rappaport exercised stock options and subsequently gifted the acquired shares to a family foundation.

Summary

• Andrew Rappaport, a Director of Olema Pharmaceuticals, Inc. (OLMA), reported transactions involving the company's common stock.
• On November 21, 2025, Rappaport acquired 35,868 shares of common stock by exercising stock options at a price of $0.39 per share.
• On November 25, 2025, he disposed of the same 35,868 shares as a bona fide gift to the Rappaport Family Foundation for no consideration.
• Rappaport retains voting and dispositive power over the shares held by the foundation.
• Following these transactions, Rappaport directly owns 0 shares but indirectly owns 385,965 shares through the Rappaport Family Trust, where he is a co-trustee.

Sentiment

Score: 6

Explanation: The filing reports a standard insider transaction involving the exercise of stock options and a subsequent charitable gift of the acquired shares. This is a routine event for a director and does not indicate any significant positive or negative operational or financial news for the company itself, though the philanthropic act is generally viewed favorably.

Positives

• The gift of shares to a charitable foundation demonstrates philanthropic activity by a company director.
• The exercise of options indicates the director is realizing value from previously granted equity.

Negatives

• The direct ownership of shares by the director decreased to zero following the gift, although indirect control over the gifted shares and other shares through a trust remains.

Future Outlook

No specific future outlook or guidance is provided in this insider transaction report.

Industry Context

This filing is a standard insider transaction report, common for publicly traded companies, detailing a director's equity activities. It does not provide information related to broader industry trends or competitive landscape.

Related Party Transactions

• The transfer of 35,868 shares to the Rappaport Family Foundation, where the reporting person is an officer and retains voting and dispositive power, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The transactions are routine and do not directly impact the company's operational performance or financial health. The slight increase in shares outstanding from option exercise is negligible.
• Charitable Organizations: The Rappaport Family Foundation benefits from the gift of shares.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director exercised options and then gifted the shares to a family foundation. Such transactions are common and typically do not provide new material information about the company's operational performance or future prospects that would warrant a change in investment recommendation. The director's indirect ownership remains substantial. Therefore, a "hold" recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Olema Pharmaceuticals, OLMA, Form 4, Insider Transaction, Stock Option Exercise, Share Gift, Andrew Rappaport, Director, Beneficial Ownership